- Conditions
- Acute Myeloid Leukemia
- Interventions
- Text Message-Based Navigation Intervention, Behavioral, Psychological or Informational Intervention, Survey Administration, Quality-of-Life Assessment
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 5,940
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Anemia
- Interventions
- Roxadustat
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 4
- States / cities
- Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
- Interventions
- THE-630
- Drug
- Lead sponsor
- Theseus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Miami, Florida + 4 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
- Interventions
- CC-223, erlotinib, CC-223, oral azacitidine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • New York, New York + 4 more
- Conditions
- Hypersensitivity Reactions
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Irreversible Pulpitis, Apical Periodontitis, Pulpal Necrosis
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Microbiome, Cytokines, Plaque, Gingivitis, Gingival Bleeding
- Interventions
- Distilled Water, Marketed Comparator 1, Marketed Comparator 2, Prototype Rinse 1, Prototype Rinse 2
- Other
- Lead sponsor
- Kenvue Brands LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Somerville, Massachusetts
- Conditions
- Hyponatremia
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
- Conditions
- Very Low Birth Weight Infant, Premature Infants, Anemia of Prematurity, Iron Deficiency, Anaemia in Children, Extremely Low Birth Weight
- Interventions
- 6 mg/kg of oral iron as ferrous sulfate administered every other day., 6 mg/kg of oral iron as ferrous sulfate administered every day.
- Dietary Supplement
- Lead sponsor
- CHRISTUS Health
- Other
- Eligibility
- 26 Weeks to 32 Weeks
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Xerostomia, Sjogren's Syndrome
- Interventions
- P-552, Placebo
- Drug
- Lead sponsor
- Parion Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Medication Event Monitoring System
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy Volunteers
- Interventions
- Galicaftor, ABBV-576, Navocaftor, Midazolam
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Anaheim, California • Miami, Florida • Las Vegas, Nevada + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- Docosahexanoic Acid Supplement, Placebo
- Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more
- Conditions
- Thrombocytopaenia
- Interventions
- SB497115, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Greenbrae, California + 23 more
- Conditions
- Advanced Solid Tumor, Lymphoma
- Interventions
- DS-3078a
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Osteoporosis
- Interventions
- Ronacaleret
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Port Orange, Florida
- Conditions
- Vitamin D Deficiency
- Interventions
- Oral Vitamin D3, Ultraviolet Light
- Dietary Supplement · Radiation
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma
- Interventions
- GP MDI, BFF MDI, Placebo MDI
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Lancaster, California • Long Beach, California + 12 more
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Interventions
- CP-547,632
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Santa Monica, California • Baltimore, Maryland + 2 more
- Conditions
- Obesity and Overweight
- Interventions
- NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
- Drug
- Lead sponsor
- Biomed Industries, Inc.
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 5 more
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more
- Conditions
- Primary Sjögren Syndrome, Dry Eye
- Interventions
- 0.005% Lacripep, 0.01% Lacripep, Placebo
- Drug
- Lead sponsor
- TearSolutions, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Azusa, California + 31 more
- Conditions
- Oral Leukoplakia
- Interventions
- 5-fluorouracil
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California